TRIM22 antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | Q8IYM9 |
Other Accession | NM_006074, NP_006065 |
Reactivity | Human |
Predicted | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 57kDa |
Gene ID | 10346 |
---|---|
Alias Symbol | GPSTAF50, RNF94, STAF50 |
Other Names | E3 ubiquitin-protein ligase TRIM22, 6.3.2.-, 50 kDa-stimulated trans-acting factor, RING finger protein 94, Staf-50, Tripartite motif-containing protein 22, TRIM22, RNF94, STAF50 |
Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reconstitution & Storage | Add 50 ul of distilled water. Final anti-TRIM22 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
Precautions | TRIM22 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TRIM22 |
---|---|
Synonyms | RNF94, STAF50 |
Function | Interferon-induced E3 ubiquitin ligase that plays important roles in innate and adaptive immunity (PubMed:25683609, PubMed:35777501). Restricts the replication of many viruses including HIV-1, encephalomyocarditis virus (EMCV), hepatitis B virus (HBV), hepatitis C virus (HCV) or Zika virus (ZIKV) (PubMed:25683609, PubMed:35777501, PubMed:36042495). Mechanistically, negatively regulates HCV replication by promoting ubiquitination and subsequent degradation of viral NS5A (PubMed:25683609). Acts also by promoting the degradation of Zika virus NS1 and NS3 proteins through proteasomal degradation (PubMed:36042495). Acts as a suppressor of basal HIV-1 LTR- driven transcription by preventing Sp1 binding to the HIV-1 promoter (PubMed:26683615). Plays also a role in antiviral immunity by co- regulating together with NT5C2 the RIGI/NF-kappa-B pathway by promoting 'Lys-63'-linked ubiquitination of RIGI, while NT5C2 is responsible for 'Lys-48'-linked ubiquitination of RIGI (PubMed:36159777). Participates in adaptive immunity by suppressing the amount of MHC class II protein in a negative feedback manner in order to limit the extent of MHC class II induction (PubMed:35777501). |
Cellular Location | Cytoplasm. Nucleus Nucleus speckle. Nucleus, Cajal body. Note=Localizes predominantly to the nucleus, found in cytoplasm to some extent. Forms distinct nuclear bodies that undergo dynamic changes during cell cycle progression Nuclear bodies start to form in the early G0/G1 phase but become speckle-like in the S-phase and completely dispersed in mitosis. 35% of TRIM22 nuclear bodies overlap or are found adjacent to Cajal bodies |
Tissue Location | Strongly expressed in peripheral blood leukocytes, spleen, thymus, and ovary. Expressed at basal levels in other tissues |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Interferon-induced antiviral protein involved in cell innate immunity. The antiviral activity could in part be mediated by TRIM22-dependent ubiquitination of viral proteins. Plays a role in restricting the replication of HIV-1, encephalomyocarditis virus (EMCV) and hepatitis B virus (HBV). Acts as a transcriptional repressor of HBV core promoter. May have E3 ubiquitin-protein ligase activity.
References
Tissot C.,et al.J. Biol. Chem. 270:14891-14898(1995).
Reymond A.,et al.EMBO J. 20:2140-2151(2001).
Obad S.,et al.Oncogene 23:4050-4059(2004).
Duan Z.,et al.Biochem. Biophys. Res. Commun. 374:502-506(2008).
Barr S.D.,et al.PLoS Pathog. 4:E1000007-E1000007(2008).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.